N/A N=159 TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
Malaria · Falciparum Malaria · Vivax Malaria
Primary: Early Treatment Failure (ETF) — 0; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=22 Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy
Non-small Cell Lung Cancer
Primary: Number of Participants With a Change From Baseline in Ventilation Map Using Hyperpolarized Xe-129 MR Imaging — 6 Participants — p=0.041
Phase 3 N=643 GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease
Alzheimer Disease
Primary: Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog 11) — 23.7; 23.4; 23.6; 26.6 score on a scale — p=<0.0455
Phase 4 N=55 A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
Psoriasis
Primary: Improvement in Quality of Life Measured by Change From Baseline in Psychological General Well-Being Scale — 78; 3.7; 8.0 score on a scale — p=<0.001
Phase 4 N=16 Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics
Genotype 1 Hepatitis C Virus
Primary: The Number of Subjects Who Achieve Negative RNA in Alcoholics — 14 Participants
Phase 3 N=189 L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects
Acute Lung Injury
Primary: A Composite Variable Consisting of the Longer of Either (1) Length of Time on Mechanical Ventilation or (2) Length of Inotrope Use. — 3351.1; 3549.6 Minutes — p=0.4930
Phase 2 N=70 Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal
Cannabis Dependence
Primary: Change in Marijuana Withdrawal Checklist (MWC) — 6.04; 11 score on a scale
N/A N=669 A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmithKline [GSK] Biologicals' Human Papillomavirus [HPV] -16/18 Vaccine), When Administered According to the Approved Prescribing Information (PI) in Korea
Neoplasms, Rectal
Primary: Percentage (%) of Subjects With Adverse Events (AEs) Post Dose 1 — 17.72 Percentage of subjects
Phase 2 N=147 Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
Cholangiocarcinoma
Primary: Objective Response Rate (ORR) in Participants With FGFR2 Rearrangements or Fusions — 37.0 percentage of participants
N/A N=105 Prevention of Musculoskeletal Injuries in Slovenian Armed Forces
Knee Injuries and Disorders · Ankle Injuries and Disorders · Low Back Pain
Primary: Number of Soldiers With Ankle and Knee Injuries — 1; 3 Participants — p=0.134
Phase 3 N=230 Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
Attention Deficit Hyperactivity Disorder · ADHD
Primary: Change in ADHD-RS-IV Total Score From Baseline (Visit 2) to the End of the Double-Blind Phase (Visit 3) — 9.3; 11.2; 12.3; 13.2 units on a scale — p=0.0046
Phase 2 N=67 Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
BRCA1 Mutation Carrier · BRCA2 Mutation Carrier · Ductal Breast Carcinoma In Situ
Primary: Mean Levels of Telapristone Acetate in Breast Tissue — 2.82; 103 ng/g
Phase 2 N=172 To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease
Dry Eye
Primary: Photographic Assessment of Bulbar Conjunctival Hyperemia Change in Score From Baseline (CFB) at 15 Days (Evaluated Via Central Reading Center). — -0.51; -0.43; -0.21…
Phase 1 N=93 Differential Responses to Drugs and Sweet Tastes
Bipolar II Disorder
Primary: Change in Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). — 18.88…
Phase 2 N=28 Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
Endometrial Cancer · Recurrent Endometrial Cancer
Primary: Clinical Benefit Rate (CBR) — 7; 18 Participants